MDxHealth, Merck KGaA Extend Deal for Cancer Trial | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDxHealth today announced the extension of a deal with Merck KGaA for the use of its MGMT assay in Merck's brain cancer drug clinical trials.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.